Verona Pharma plc

NasdaqGM VRNA

Verona Pharma plc Shares (Diluted, Weighted) for the year ending December 31, 2023: 79,267,832

Verona Pharma plc Shares (Diluted, Weighted) is 79,267,832 for the year ending December 31, 2023, a 19.86% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Verona Pharma plc Shares (Diluted, Weighted) for the year ending December 31, 2022 was 66,133,940, a 11.81% change year over year.
Verona Pharma plc Shares (Diluted, Weighted) for the year ending December 31, 2021 was 59,148,557, a 79.97% change year over year.
Verona Pharma plc Shares (Diluted, Weighted) for the year ending December 31, 2020 was 32,866,581, a 149.64% change year over year.
Verona Pharma plc Shares (Diluted, Weighted) for the year ending December 31, 2019 was 13,165,829, a -89.98% change year over year.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

NasdaqGM: VRNA

Verona Pharma plc

CEO	Dr. David S. Zaccardelli Pharm.D.
IPO Date	April 28, 2017
Location	United Kingdom
Headquarters	3 More London Riverside
Employees	79
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Composite Materials Pollution Treatment

Description

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Key trends

Past 5 years